prednisolone, oncovin, cyclophosphamide, and doxorubicin hydrochloride (R-EPOCH), etc., are being considered as potential treatments. 2 The median overall survival of MYC-BCL6 DHL patients is reported to be 17.2 months, and the 1-year survival rate is 58%, which is considered to be similar to that of MYC-BCL2 DHL patients. 3 One of the reasons that we performed chemotherapy on this patient was the improvement of her general condition and renal dysfunction after steroid pulse therapy. As her renal dysfunction was caused by interstitial nephritis, steroid administration may have resulted in its improvement. In addition, it is assumed that the patient's malignant lymphoma originally metastasized to the adrenal glands, resulting in a decrease in physiological steroid production, and steroid supplementation may have improved her general condition.Another reason that chemotherapy was performed on this patient is associated with the cancer pharmacotherapy guidelines for the elderly. 4 The guidelines suggest that comprehensive geriatric assessment (CGA) should not be used to determine treatment strategies for elderly DLBCL patients. As DLBCL often responds favorably to chemotherapy, we suggest that chemotherapy should be performed regardless of CGA results. In the present case, the possibility of DLBCL was considered in the pathological interim report, which encouraged us to try chemotherapy without relying on the CGA evaluation. However, the use of chemotherapy for DLBCL patient in these guidelines is only a "suggestion," and as this patient was ultimately diagnosed as having DHL, we believe that more caution should be exercised in making decisions to perform chemotherapy.Elderly patients with malignant lymphoma require a more comprehensive evaluation than younger patients regarding whether or not treatment should be performed. On the other hand, active treatment that is not necessarily bound by the results of geriatric functional evaluation may be effective, and we believe that this case demonstrates this point.